CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 27 enrolled
Drug / intervention
Psilocybindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03181529
NCT03181529Phase 2Completed
CompareCT.gov

Effects of Psilocybin in Major Depressive Disorder

Johns Hopkins University·interventional·Posted Jun 8, 2017·Updated Dec 15, 2021

In Brief

A Phase 2 clinical trial evaluating Psilocybin for Major Depressive Disorder. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The proposed pilot study will assess whether people with major depressive disorder experience psychological and behavioral benefits and/or harms from psilocybin. This study will investigate acute and persisting effects of psilocybin on depressive symptoms and other moods, attitudes, and behaviors. The primary hypothesis is that psilocybin will lead to rapid and sustained antidepressant response, as measured with standard depression rating scales.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 8, 2017
Enrollment StartAug 10, 2017
Primary CompletionDec 2, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.1 years ago

Interventions

Psilocybindrug

Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.